Tegsedi (inotersen) is an oligonucleotide pharmaceutical. Inotersen was first approved as Tegsedi on 2018-07-06. It is used to treat familial amyloid neuropathies in the USA. It has been approved in Europe to treat amyloidosis. Tegsedi's patents are valid until 2031-04-29 (FDA).
|Indication||amyloidosis, familial amyloid neuropathies|
|Drug Class||Antisense oligonucleotides|